Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...

Abbott's medtech division has consistently contributed to overall growth, with expectations for double-digit expansion from 2024 to 2026. Abbott's stock is currently valued at 22.3 times the ...

On Thursday, Piper Sandler initiated coverage on Abbott Laboratories (NYSE:NYSE:ABT) stock, assigning an Overweight rating and setting a price target of $131. The firm highlighted the company's ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price target of $133.00. The company’s shares ...

On Thursday, Piper Sandler initiated coverage on Abbott Laboratories (NYSE:NYSE:ABT) stock, assigning an Overweight rating and setting a price target of $131. The firm highlighted the company's strong ...

NEW BEAUNFELS, Texas - Governor Greg Abbott delivered remarks at an event presenting the keys for a brand new, specialty ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant ... The company had expanded too, with branches in New York, San Francisco, Seattle and Toronto ...

O'Melveny & Myers is defending Abbott Laboratories in a pending class action against the company and two other co-defendants, Procter & Gamble and SPD Swiss Precision Diagnostics GMBH. The ...

Abbott Laboratories' (NYSE:ABT) stock up by 8.7% over the past three months. Since the market usually pay for a... We recently compiled a list of the Jim Cramer’s Top 10 Stock Picks You Can’t ...